Cyrus J. Lawrence LLC Purchases 105 Shares of Stryker Co. (NYSE:SYK)

Cyrus J. Lawrence LLC grew its position in Stryker Co. (NYSE:SYK) by 0.4% in the second quarter, HoldingsChannel.com reports. The firm owned 23,637 shares of the medical technology company’s stock after acquiring an additional 105 shares during the period. Stryker accounts for approximately 1.6% of Cyrus J. Lawrence LLC’s investment portfolio, making the stock its 28th biggest holding. Cyrus J. Lawrence LLC’s holdings in Stryker were worth $8,042,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of SYK. Burkett Financial Services LLC bought a new position in Stryker in the 4th quarter worth $25,000. DSM Capital Partners LLC purchased a new stake in shares of Stryker during the fourth quarter worth about $34,000. Central Pacific Bank Trust Division bought a new stake in Stryker during the 1st quarter valued at approximately $39,000. Accent Capital Management LLC purchased a new position in Stryker in the 4th quarter worth approximately $60,000. Finally, Sachetta LLC boosted its stake in Stryker by 16.3% in the 2nd quarter. Sachetta LLC now owns 242 shares of the medical technology company’s stock worth $80,000 after purchasing an additional 34 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on SYK. Royal Bank of Canada reiterated an “outperform” rating and set a $386.00 price objective on shares of Stryker in a research report on Wednesday, July 31st. Wolfe Research began coverage on shares of Stryker in a report on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price target on the stock. BTIG Research increased their price objective on shares of Stryker from $360.00 to $374.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Needham & Company LLC lifted their target price on Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Finally, Stifel Nicolaus dropped their price target on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $378.58.

Stryker Trading Down 0.1 %

Shares of SYK opened at $364.81 on Monday. The company’s fifty day simple moving average is $345.12 and its 200-day simple moving average is $342.81. The company has a market cap of $138.97 billion, a P/E ratio of 41.64, a P/E/G ratio of 2.87 and a beta of 0.91. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $374.63.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company had revenue of $5.42 billion for the quarter, compared to analyst estimates of $5.40 billion. During the same period in the prior year, the company posted $2.54 EPS. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. As a group, analysts expect that Stryker Co. will post 12 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Monday, September 30th. Stryker’s payout ratio is currently 36.53%.

Insider Buying and Selling at Stryker

In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the completion of the sale, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Stryker news, Director Ronda E. Stryker sold 190,000 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total transaction of $61,457,400.00. Following the transaction, the director now directly owns 3,316,608 shares in the company, valued at approximately $1,072,790,023.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Glenn S. Boehnlein sold 20,000 shares of Stryker stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the sale, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. The disclosure for this sale can be found here. Insiders have sold 220,068 shares of company stock valued at $71,811,372 in the last quarter. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.